Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PI3K

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Novartis’ blood cancer therapy Kymriah recommended by NICE for routine NHS use

In England, ALL is responsible for around 300 new diagnoses every year in people aged 25 years and under

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

- PMLiVE

Novartis shares positive real-world data for Leqvio in atherosclerotic CVD

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

- PMLiVE

Novartis’ Fabhalta recommended by CHMP to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

Novartis shares positive results for spinal muscular atrophy gene therapy Zolgensma

The company said the results support the use of the one-time therapy in older and heavier children

- PMLiVE

Novartis and Genentech’s Xolair shown to significantly reduce allergic reactions to food

Food-related anaphylaxis results in 30,000 emergency room visits in the US each year

- PMLiVE

Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

- PMLiVE

ICR scientists identify new way to study important driver of breast cancer

Researchers used a technique to identify specific molecular details of biotin-labelled proteins

- PMLiVE

ICR researchers reveal how advanced breast cancers become resistant to hormone therapy

F404 mutations combined with pre-existing mutations caused resistance to fulvestrant

- PMLiVE

Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition

The deal includes an investigational therapy being evaluated in myelofibrosis

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links